Identification and characterization of the major Huperzine A metabolite in rat blood

Gregory E. Garcia, Rickey P. Hicks, David Skanchy, Deborah R. Moorad-Doctor, Bhupendra P. Doctor, Haresh S. Ved

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Huperzine A (Hup A) is under investigation as a treatment of Alzheimer's disease because of its properties of reversible and specific AChE inhibition. It has additional interesting pharmacological effects such as the protection of primary neuronal cells isolated from embryonic rat brains from glutamate-induced toxicity. We have isolated a new compound which has similar absorbance characteristics as Hup A from blood of rats administered Hup A. Monitoring the effluent from reversed-phase high-performance liquid chromatography (RP-HPLC) of blood collected 60 min after Hup A treatment at an absorbance of 308 nm (λmax for Hup A), yielded a peak height and area for this compound that was ∼1.4-fold the initial Hup A peak. The compound was isolated from RP-HPLC fractions from blood and liver for analysis by mass spectrometry and nuclear magnetic resonance (NMR). The compound gave an (M+H)+ ion with m/z 259 in positive ion mode, yielding a molecular weight (MW) of 258. If derived from Hup A (MW 242), the change in MW indicates a mass gain of 16. This would be consistent with the addition of a single oxygen or a hydroxylation. To determine the location of the modification, it was examined by 1H NMR, and it was found that the added mass was due to a single epoxidation yielding 13,14-epoxy Hup-A.

Original languageEnglish (US)
Pages (from-to)379-383
Number of pages5
JournalJournal of Analytical Toxicology
Volume28
Issue number5
DOIs
StatePublished - Jan 1 2004

Fingerprint

Metabolites
Rats
metabolite
Blood
blood
Molecular weight
High performance liquid chromatography
absorbance
nuclear magnetic resonance
liquid chromatography
Nuclear magnetic resonance
Hydroxylation
Epoxidation
ion
Molecular Weight
Reverse-Phase Chromatography
Liver
Mass spectrometry
Toxicity
brain

ASJC Scopus subject areas

  • Analytical Chemistry
  • Environmental Chemistry
  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety

Cite this

Garcia, G. E., Hicks, R. P., Skanchy, D., Moorad-Doctor, D. R., Doctor, B. P., & Ved, H. S. (2004). Identification and characterization of the major Huperzine A metabolite in rat blood. Journal of Analytical Toxicology, 28(5), 379-383. https://doi.org/10.1093/jat/28.5.379

Identification and characterization of the major Huperzine A metabolite in rat blood. / Garcia, Gregory E.; Hicks, Rickey P.; Skanchy, David; Moorad-Doctor, Deborah R.; Doctor, Bhupendra P.; Ved, Haresh S.

In: Journal of Analytical Toxicology, Vol. 28, No. 5, 01.01.2004, p. 379-383.

Research output: Contribution to journalArticle

Garcia, GE, Hicks, RP, Skanchy, D, Moorad-Doctor, DR, Doctor, BP & Ved, HS 2004, 'Identification and characterization of the major Huperzine A metabolite in rat blood', Journal of Analytical Toxicology, vol. 28, no. 5, pp. 379-383. https://doi.org/10.1093/jat/28.5.379
Garcia, Gregory E. ; Hicks, Rickey P. ; Skanchy, David ; Moorad-Doctor, Deborah R. ; Doctor, Bhupendra P. ; Ved, Haresh S. / Identification and characterization of the major Huperzine A metabolite in rat blood. In: Journal of Analytical Toxicology. 2004 ; Vol. 28, No. 5. pp. 379-383.
@article{f212a383e0cb4de58f50b632340abab3,
title = "Identification and characterization of the major Huperzine A metabolite in rat blood",
abstract = "Huperzine A (Hup A) is under investigation as a treatment of Alzheimer's disease because of its properties of reversible and specific AChE inhibition. It has additional interesting pharmacological effects such as the protection of primary neuronal cells isolated from embryonic rat brains from glutamate-induced toxicity. We have isolated a new compound which has similar absorbance characteristics as Hup A from blood of rats administered Hup A. Monitoring the effluent from reversed-phase high-performance liquid chromatography (RP-HPLC) of blood collected 60 min after Hup A treatment at an absorbance of 308 nm (λmax for Hup A), yielded a peak height and area for this compound that was ∼1.4-fold the initial Hup A peak. The compound was isolated from RP-HPLC fractions from blood and liver for analysis by mass spectrometry and nuclear magnetic resonance (NMR). The compound gave an (M+H)+ ion with m/z 259 in positive ion mode, yielding a molecular weight (MW) of 258. If derived from Hup A (MW 242), the change in MW indicates a mass gain of 16. This would be consistent with the addition of a single oxygen or a hydroxylation. To determine the location of the modification, it was examined by 1H NMR, and it was found that the added mass was due to a single epoxidation yielding 13,14-epoxy Hup-A.",
author = "Garcia, {Gregory E.} and Hicks, {Rickey P.} and David Skanchy and Moorad-Doctor, {Deborah R.} and Doctor, {Bhupendra P.} and Ved, {Haresh S.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1093/jat/28.5.379",
language = "English (US)",
volume = "28",
pages = "379--383",
journal = "Journal of Analytical Toxicology",
issn = "0146-4760",
publisher = "Preston Publications",
number = "5",

}

TY - JOUR

T1 - Identification and characterization of the major Huperzine A metabolite in rat blood

AU - Garcia, Gregory E.

AU - Hicks, Rickey P.

AU - Skanchy, David

AU - Moorad-Doctor, Deborah R.

AU - Doctor, Bhupendra P.

AU - Ved, Haresh S.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Huperzine A (Hup A) is under investigation as a treatment of Alzheimer's disease because of its properties of reversible and specific AChE inhibition. It has additional interesting pharmacological effects such as the protection of primary neuronal cells isolated from embryonic rat brains from glutamate-induced toxicity. We have isolated a new compound which has similar absorbance characteristics as Hup A from blood of rats administered Hup A. Monitoring the effluent from reversed-phase high-performance liquid chromatography (RP-HPLC) of blood collected 60 min after Hup A treatment at an absorbance of 308 nm (λmax for Hup A), yielded a peak height and area for this compound that was ∼1.4-fold the initial Hup A peak. The compound was isolated from RP-HPLC fractions from blood and liver for analysis by mass spectrometry and nuclear magnetic resonance (NMR). The compound gave an (M+H)+ ion with m/z 259 in positive ion mode, yielding a molecular weight (MW) of 258. If derived from Hup A (MW 242), the change in MW indicates a mass gain of 16. This would be consistent with the addition of a single oxygen or a hydroxylation. To determine the location of the modification, it was examined by 1H NMR, and it was found that the added mass was due to a single epoxidation yielding 13,14-epoxy Hup-A.

AB - Huperzine A (Hup A) is under investigation as a treatment of Alzheimer's disease because of its properties of reversible and specific AChE inhibition. It has additional interesting pharmacological effects such as the protection of primary neuronal cells isolated from embryonic rat brains from glutamate-induced toxicity. We have isolated a new compound which has similar absorbance characteristics as Hup A from blood of rats administered Hup A. Monitoring the effluent from reversed-phase high-performance liquid chromatography (RP-HPLC) of blood collected 60 min after Hup A treatment at an absorbance of 308 nm (λmax for Hup A), yielded a peak height and area for this compound that was ∼1.4-fold the initial Hup A peak. The compound was isolated from RP-HPLC fractions from blood and liver for analysis by mass spectrometry and nuclear magnetic resonance (NMR). The compound gave an (M+H)+ ion with m/z 259 in positive ion mode, yielding a molecular weight (MW) of 258. If derived from Hup A (MW 242), the change in MW indicates a mass gain of 16. This would be consistent with the addition of a single oxygen or a hydroxylation. To determine the location of the modification, it was examined by 1H NMR, and it was found that the added mass was due to a single epoxidation yielding 13,14-epoxy Hup-A.

UR - http://www.scopus.com/inward/record.url?scp=3242687012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242687012&partnerID=8YFLogxK

U2 - 10.1093/jat/28.5.379

DO - 10.1093/jat/28.5.379

M3 - Article

C2 - 15239859

AN - SCOPUS:3242687012

VL - 28

SP - 379

EP - 383

JO - Journal of Analytical Toxicology

JF - Journal of Analytical Toxicology

SN - 0146-4760

IS - 5

ER -